PAD News

Some practices may have received a Healthcare Professionals Letter from Novo Nordisk regarding an imminent change to the formulation of Rybelsus® (oral semaglutide). The updated formulation offers improved bioavailability, meaning lower doses are now required to achieve the same therapeutic effect.
As part of this change, three new lower-strength tablets (1.5mg, 4mg and 9mg - also smaller in size) have been manufactured and will replace the three existing strengths (3mg, 7mg and 14mg). Further details can be found in the Risk Minimisation Materials available here: Rybelsus Patient Transition Guide

For a transitional period, both the old and new strengths will be available. However, the original formulation is expected to be phased out and become unavailable by the end of the year.
Patients will need to be counselled appropriately and switched to the appropriate strength of the new formulation using the Rybelsus Patient Transition Guide.